Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease

Current Opinion in Pharmacology

Volumn 20, Issue , 2015, Pages 29-34

  Amalric, Marianne ^a  

^a AIX MARSEILLE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; G PROTEIN COUPLED RECEPTOR; LEVODOPA; LIGAND; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 4; METABOTROPIC RECEPTOR 7; METABOTROPIC RECEPTOR 8; ANTIPARKINSON AGENT; DOPAMINE; GLUTAMIC ACID;

AKINESIA; ARTICLE; BASAL GANGLION; BRADYKINESIA; COGNITIVE DEFECT; DEPRESSION; DRUG TOLERABILITY; EMOTIONAL DISORDER; GLOBUS PALLIDUS; HUMAN; LIGAND BINDING; PARKINSON DISEASE; PATHOGENESIS; RIGIDITY; SCHIZOPHRENIA; SUBTHALAMIC NUCLEUS; SYMPTOMATOLOGY; TREMOR; ANIMAL; DRUG EFFECTS; DYSKINESIA, DRUG-INDUCED; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY;

ANIMALS; ANTIPARKINSON AGENTS; BASAL GANGLIA; DOPAMINE; DYSKINESIA, DRUG-INDUCED; GLUTAMIC ACID; HUMANS; LEVODOPA; MOLECULAR TARGETED THERAPY; PARKINSON DISEASE; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 84911403945     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2014.11.001     Document Type: Review

References (64)

1. Wichmann T, Delong MR: Anatomy and physiology of the basal ganglia: relevance to Parkinson's disease and related disorders. Handb Clin Neurol 2007, 83:1-18.
2. Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P: Parkinson's disease: the non-motor issues. Parkinsonism Relat Disord 2011, 17:717-723.
3. Pin JP, Duvoisin R: The metabotropic glutamate receptors: structure and functions. Neuropharmacology 1995, 34:1-26.
4. Pin J-P, Acher F: The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. Curr Drug Targets CNS Neurol Disord 2002, 1:297-317.
5. Conn PJ, Pin JP: Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997, 37:205-237.
6. Nakanishi S, Nakajima Y, Masu M, Ueda Y, Nakahara K, Watanabe D, Yamaguchi S, Kawabata S, Okada M: Glutamate receptors: brain function and signal transduction. Brain Res Brain Res Rev 1998, 26:230-235.
7. Conn PJ, Battaglia G, Marino MJ, Nicoletti F: Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci 2005, 6:787-798.
8. Hovelsø N, Sotty F, Montezinho LP, Pinheiro PS, Herrik KF, Mørk A: Therapeutic potential of metabotropic glutamate receptor modulators. Curr Neuropharmacol 2012, 10:12.
9. Nicoletti F, Bockaert J, Collingridge GL, Conn PJ, Ferraguti F, Schoepp DD, Wroblewski JT, Pin JP: Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology 2011, 60:1017-1041.
10. Ossowska K, Konieczny J, Wardas J, Pietraszek M, Kuter K, Wolfarth S, Pilc A: An influence of ligands of metabotropic glutamate receptor subtypes on parkinsonian-like symptoms and the striatopallidal pathway in rats. Amino Acids 2007, 32:179-188.
11. Phillips JM, Lam HA, Ackerson LC, Maidment NT: Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease. Eur J Neurosci 2006, 23:151-160.
12. Battaglia G, Busceti CL, Molinaro G, Biagioni F, Storto M, Fornai F, Nicoletti F, Bruno V: Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J Neurosci 2004, 24:828-835.
13. Masilamoni GJ, Bogenpohl JW, Alagille D, Delevich K, Tamagnan G, Votaw JR, Wichmann T, Smith Y: Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. Brain J Neurol 2011, 134:2057-2073.
14. Ferraguti F, Shigemoto R: Metabotropic glutamate receptors. Cell Tissue Res 2006, 326:483-504.
15. Paquet M, Smith Y: Group I metabotropic glutamate receptors in the monkey striatum: subsynaptic association with glutamatergic and dopaminergic afferents. J Neurosci 2003, 23:7659-7669.
16. Conn PJ, Lindsley CW, Meiler J, Niswender CM: Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat Rev Drug Discov 2014, 13:692-708.
17. Poisik OV, Smith Y, Conn PJ: D1- and D2-like dopamine receptors regulate signaling properties of group I metabotropic glutamate receptors in the rat globus pallidus. Eur J Neurosci 2007, 26:852-862.
18. Gasparini F, Di Paolo T, Gomez-Mancilla B: Metabotropic glutamate receptors for Parkinson's disease therapy. Park Dis 2013, 2013:1-11.
19. Breysse N, Amalric M, Salin P: Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats. J Neurosci 2003, 23:8302-8309.
20. Breysse N, Baunez C, Spooren W, Gasparini F, Amalric M: Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci 2002, 22:5669-5678.
21. Coccurello R, Breysse N, Amalric M: Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacol 2004, 29:1451-1461.
22. Oueslati A, Breysse N, Amalric M, Kerkerian-Le Goff L, Salin P: Dysfunction of the cortico-basal ganglia-cortical loop in a rat model of early parkinsonism is reversed by metabotropic glutamate receptor 5 antagonism. Eur J Neurosci 2005, 22:2765-2774.
23. Rascol O, Fox S, Gasparini F, Kenney C, Di Paolo T, Gomez-Mancilla B: Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism Relat Disord 2014 http://dx.doi.org/10.1016/j.parkreldis.2014.05.003. (Internet).
24. Samadi P, Grégoire L, Morissette M, Calon F, Hadj Tahar A, Dridi M, Belanger N, Meltzer LT, Bédard PJ, Di Paolo T: mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol Aging 2008, 29:1040-1051.
25. Sanchez-Pernaute R, Wang J-Q, Kuruppu D, Cao L, Tueckmantel W, Kozikowski A, Isacson O, Brownell A-L: Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates. Neuroimage 2008, 42:248-251.
26. Ouattara B, Grégoire L, Morissette M, Gasparini F, Vranesic I, Bilbe G, Johns DR, Rajput A, Hornykiewicz O, Rajput AH et al.: Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiol Aging 2011, 32:1286-1295.
27. Bastide MF, Dovero S, Charron G, Porras G, Gross CE, Fernagut P-O, Bézard E: Immediate-early gene expression in structures outside the basal ganglia is associated to L-DOPA-induced dyskinesia. Neurobiol Dis 2014, 62:179-192.
28. Engeln M, Bastide MF, Toulmé E, Dehay B, Bourdenx M, Doudnikoff E, Li Q, Gross CE, Boué-Grabot E, Pisani A et al.: Selective inactivation of striatal FosB/DFosB-expressing neurons alleviates L-DOPA-induced dyskinesia. Biol Psychiatry 2014 http://dx.doi.org/10.1016/j.biopsych.2014.07.007.
29. Picconi B, Pisani A, Centonze D, Battaglia G, Storto M, Nicoletti F, Bernardi G, Calabresi P: Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. Brain J Neurol 2002, 125:2635-2645.
30. Picconi B, Calabresi P: Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease? Mov Disord 2014, 29:715-719.
31. Rylander D, Recchia A, Mela F, Dekundy A, Danysz W, Cenci MA: Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J Pharmacol Exp Ther 2009, 330:227-235.
32. Murray TK, Messenger MJ, Ward MA, Woodhouse S, Osborne DJ, Duty S, O'Neill MJ: Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease. Pharmacol Biochem Behav 2002, 73:455-466.
33. Samadi P, Grégoire L, Morissette M, Calon F, Hadj Tahar A, Bélanger N, Dridi M, Bédard PJ, Di Paolo T: Basal ganglia group II metabotropic glutamate receptors specific binding in nonhuman primate model of L-DOPA-induced dyskinesias. Neuropharmacology 2008, 54:258-268.
34. Duty S: Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease: Group III mGlu receptors in PD. Br J Pharmacol 2010, 161:271-287.
35. Célanire S, Campo B: Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders. Expert Opin Drug Discov 2012, 7:261-280.
36. Le Poul E, Bolea C, Girard F, Poli S, Charvin D, Campo B, Bortoli J, Bessif A, Luo B, Koser AJ et al.: A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease. J Pharmacol Exp Ther 2012, 343:167-177.
37. Jones CK, Engers DW, Thompson AD, Field JR, Blobaum AL, Lindsley SR, Zhou Y, Gogliotti RD, Jadhav S, Zamorano R et al.: Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1- yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu4) with oral efficacy in an antiparkinsonian animal model. J Med Chem 2011, 54:7639-7647.
38. Bennouar K-E, Uberti MA, Melon C, Bacolod MD, Jimenez HN, Cajina M, Kerkerian-Le Goff L, Doller D, Gubellini P: Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia. Neuropharmacology 2013, 66:158-169.
39. Gubellini P, Melon C, Dale E, Doller D, Kerkerian-Le Goff L: Distinct effects of mGlu4 receptor positive allosteric modulators at corticostriatal vs. striatopallidal synapses may differentially contribute to their antiparkinsonian action. Neuropharmacology 2014, 85:166-177.
40. Acher FC, Selvam C, Pin J-P, Goudet C, Bertrand H-O: A critical pocket close to the glutamate binding site of mGlu receptors opens new possibilities for agonist design. Neuropharmacology 2011, 60:102-107.
41. Beurrier C, Lopez S, Révy D, Selvam C, Goudet C, Lhérondel M, Gubellini P, Kerkerian-LeGoff L, Acher F, Pin J-P et al.: Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J 2009, 23:3619-3628.
42. Lopez S, Jouve L, Turle-Lorenzo N, Kerkerian-Legoff L, Salin P, Amalric M: Antiparkinsonian action of a selective group III mGlu receptor agonist is associated with reversal of subthalamonigral overactivity. Neurobiol Dis 2012, 46:69-77.
43. Lopez S, Turle-Lorenzo N, Johnston TH, Brotchie JM, Schann S, Neuville P, Amalric M: Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats. Neuropharmacology 2008, 55:483-490.
44. Lopez S, Turle-Lorenzo N, Acher F, De Leonibus E, Mele A, Amalric M: Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease. J Neurosci 2007, 27:6701-6711.
45. Amalric M, Lopez S, Goudet C, Fisone G, Battaglia G, Nicoletti F, Pin J-P, Acher FC: Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson's disease. Neuropharmacology 2013, 66:53-64.
46. Goudet C, Vilar B, Courtiol T, Deltheil T, Bessiron T, Brabet I, Oueslati N, Rigault D, Bertrand H-O, McLean H et al.: A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential. FASEB J 2012, 26:1682-1693.
47. Greco B, Lopez S, van der Putten H, Flor PJ, Amalric M: Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease. J Pharmacol Exp Ther 2010, 332:1064-1071.
48. Konieczny J, Lenda T: Contribution of the mGluR7 receptor to antiparkinsonian-like effects in rats: a behavioral study with the selective agonist AMN082. Pharmacol Rep 2013, 65:1194-1203.
49. Johnson KA, Conn PJ, Niswender CM: Glutamate receptors as therapeutic targets for Parkinson's disease. CNS Neurol Disord Drug Targets 2009, 8:475-491.
50. Bonito-Oliva A, Pignatelli M, Spigolon G, Yoshitake T, Seiler S, Longo F, Piccinin S, Kehr J, Mercuri NB, Nisticò R et al.: Cognitive impairment and dentate gyrus synaptic dysfunction in experimental parkinsonism. Biol Psychiatry 2014, 75:701-710.
51. Drui G, Carnicella S, Carcenac C, Favier M, Bertrand A, Boulet S, Savasta M: Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease. Mol Psychiatry 2014, 19 :358-367.
52. Chen L, Deltheil T, Turle-Lorenzo N, Liberge M, Rosier C, Watabe I, Sreng L, Amalric M, Mourre C: SK channel blockade reverses cognitive and motor deficits induced by nigrostriatal dopamine lesions in rats. Int J Neuropsychopharmacol 2014, 17:1295-1306.
53. Calabresi P, Galletti F, Saggese E, Ghiglieri V, Picconi B: Neuronal networks and synaptic plasticity in Parkinson's disease: beyond motor deficits. Parkinsonism Relat Disord 2007, 13:S259-S262.
54. Matosin N, Newell KA: Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia. Neurosci Biobehav Rev 2013, 37:256-268.
55. Fowler SW, Walker JM, Klakotskaia D, Will MJ, Serfozo P, Simonyi A, Schachtman TR: Effects of a metabotropic glutamate receptor 5 positive allosteric modulator. CDPPB, on spatial learning task performance in rodents. Neurobiol Learn Mem 2013, 99:25-31.
56. De Leonibus E, Managò F, Giordani F, Petrosino F, Lopez S, Oliverio A, Amalric M, Mele A: Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease. Neuropsychopharmacology 2009, 34:729-738.
57. Ayala JE, Niswender CM, Luo Q, Banko JL, Conn PJ: Group III mGluR regulation of synaptic transmission at the SC-CA1 synapse is developmentally regulated. Neuropharmacology 2008, 54:804-814.
58. Matosin N, Fernandez-Enright F, Frank E, Deng C, Wong J, Huang XF, Newell KA: Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics. J Psychiatry Neurosci 2014, 39:130242.
59. Balschun D, Zuschratter W, Wetzel W: Allosteric enhancement of metabotropic glutamate receptor 5 function promotes spatial memory. Neuroscience 2006, 142:691-702.
60. Parmentier-Batteur S, Hutson PH, Menzel K, Uslaner JM, Mattson BA, O'Brien JA, Magliaro BC, Forest T, Stump CA, Tynebor RM et al.: Mechanism based neurotoxicity of mGlu5 positive allosteric modulators-development challenges for a promising novel antipsychotic target. Neuropharmacology 2014, 82:161-173.
61. O'Connor RM, Finger BC, Flor PJ, Cryan JF: Metabotropic glutamate receptor 7: at the interface of cognition and emotion. Eur J Pharmacol 2010, 639:123-131.
62. Klakotskaia D, Ramsey AK, Fowler SW, Serfozo P, Simonyi A, Schachtman TR: Effects of group II and III metabotropic glutamate receptor ligands on conditioned taste aversion learning. Behav Brain Res 2013, 253:9-16.
63. Pałucha-Poniewiera A, Szewczyk B, Pilc A: Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the mGlu7 agonist AMN082 in the FST in rats. Neuropharmacology 2014, 82:59-68.
64. DeLong M, Wichmann T: Update on models of basal ganglia function and dysfunction. Parkinsonism Relat Disord 2009, 15:S237-S240.